Researchers reviewed existing studies to compare two treatment paths for women with early-stage cervical cancer who wish to have children in the future. They looked at women with tumors at least 2 centimeters in size. One approach was to have fertility-sparing surgery right away. The other was to receive chemotherapy first to shrink the tumor, followed by the same type of surgery.
The analysis combined data from 1,453 women across multiple studies. It found that the pregnancy rate was higher for women who had chemotherapy before surgery (31%) compared to those who had surgery alone (8%). The rates of cancer coming back were 13% for the chemotherapy-first group and 10% for the surgery-only group, a difference that was not statistically significant.
The main reason to be careful with these results is that they come from observational studies, not controlled clinical trials. The studies included had a moderate-to-high risk of bias, meaning their designs might have influenced the findings. The researchers note that prospective validation is still needed.
Readers should understand that this review suggests a potential benefit for pregnancy outcomes when chemotherapy is used before fertility-sparing surgery, without a clear increase in recurrence risk in this analysis. However, this is not yet a proven standard. Women considering these options should discuss the latest evidence and their personal situation with their oncology team.